unknown
Stage
6
Investors
About
Thermosome is a biotech company developing thermosensitive liposomal drug formulations to achieve targeted tumor delivery and immune stimulation; its lead candidate THE001 (DPPG2-TSL-DOX) is a thermosensitive liposomal formulation of doxorubicin being developed for locally advanced soft tissue sarcoma in combination with regional hyperthermia.
Explore Thermosome's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.